Arecor Therapeutics collaborates with Medtronic on novel insulin

(Alliance News) - Arecor Therapeutics PLC on Thursday announced a novel insulin development collaboration with Medtronic PLC.

The West Sussex, England-based biopharmaceutical firm said it will develop high concentration, thermostable insulin alognside Medtronic in a next-generation implantable pump.

Medtronic is a Dublin-based medical device company.

According to Arecor, the new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.

"This collaboration has the potential to allow for the continued care of these patients with an insulin that may minimise the need for pump maintenance interventions and expand the utility for physicians, whilst saving healthcare costs," it said.

Arecor Chief Executive Officer Sarag Howell said: "Our leadership in this field has been demonstrated through our best-in-class ultra-rapid acting clinical development programmes (AT278 & AT247). Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients.

"We are excited to play our part in this progress with the development of a highly differentiated insulin with the potential to transform treatment for an extremely vulnerable patient group. This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices."

Arecor Therapeutics shares were up 1.3% at 69.58 pence in London on Thursday.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Arecor Therape